Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Adicet Bio (ACET).
Adicet Bio, Inc. has unveiled promising preclinical data for its innovative cancer therapy candidate, ADI-270, at the ASGCT Annual Meeting. This new therapy, which targets CD70+ cancers using gamma delta CAR T cell technology, has shown potent effectiveness against various tumor cell lines, including those with low CD70 expression. The treatment demonstrates not only strong anti-tumor responses in vivo but also resilience in suppressive tumor environments, highlighting its potential as a versatile and robust cancer treatment option. With these positive findings, Adicet Bio underscores its commitment to advancing the clinical development of ADI-270 and exploring its broad therapeutic potential.
See more data about ACET stock on TipRanks’ Stock Analysis page.